Home・Список акций・Protagonist Therapeutics Inc

Protagonist Therapeutics Inc

Закрыт

СекторЗдравоохранение

145.87 0.08

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

137.25

Макс.

146.75

Ключевые показатели
By Trading Economics
Доход	-82M 3.8M
Продажи	49M 56M
P/E Средняя по отрасли	131.197 68.51
Прибыль на акцию	0.05
Рентабельность продаж	6.711
Сотрудники	131
EBITDA	46M 2.7M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+7.78% upside

Дивиденды
By Acuity
Следующий отчет о доходах	11 авг. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	2.1B 8.5B
Предыдущая цена открытия	145.79
Предыдущая цена закрытия	145.87

Новостные настроения

By Acuity

35%

65%

120 / 340 Рейтинг в Healthcare

Protagonist Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

6 авг. 2026 г., 19:52 UTC

Social Media

News

Protagonist Therapeutics shares rise following multiple price target upgrades, including Citi's increase to $175, amid positive sentiment on drug approvals and pharmacokinetic data.

5 авг. 2026 г., 22:02 UTC

News

Protagonist Therapeutics reports Q2 net income of $162.8 million, up from a loss last year. Shares are higher in after-market trading following the results.

4 авг. 2026 г., 21:03 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, supported by their position above the 20-day moving average. No specific news was identified.

3 авг. 2026 г., 19:36 UTC

Protagonist Therapeutics Inc shares are lower today, continuing a decline since Friday. The stock is near the lower end of its one-month range.

31 июл. 2026 г., 19:36 UTC

Correlated Moves

Protagonist Therapeutics Inc is lower today amid broader weakness in the Biotechnology sector. Earlier in the session, shares pulled back from a high.

30 июл. 2026 г., 21:02 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, amid notable volatility and significant price swings since Thursday's close.

29 июл. 2026 г., 19:43 UTC

Macro Event

Protagonist Therapeutics Inc shares are lower amid market volatility following the Federal Reserve's decision to maintain interest rates, reflecting broader uncertainty.

28 июл. 2026 г., 21:01 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, maintaining a notable gain since Tuesday's close, despite no specific news identified.

27 июл. 2026 г., 20:02 UTC

Social Media

Protagonist Therapeutics shares are lower despite Jefferies raising its price target to $171 and Cowen increasing its peak royalty revenue forecast to $1.4 billion.

22 июл. 2026 г., 19:42 UTC

News

Protagonist Therapeutics Inc is trading lower today, continuing a decline since Tuesday amid rising crude oil prices and market tensions related to Iran.

21 июл. 2026 г., 19:06 UTC

Protagonist Therapeutics Inc shares are higher today, continuing an upward trend since Monday's close, supported by gains in the semiconductor sector.

20 июл. 2026 г., 19:41 UTC

News

Social Media

Protagonist Therapeutics shares are lower as analysts raise price targets and revenue forecasts ahead of Q2 earnings, despite a noted 0% probability of success for PN-881.

Сравнение c конкурентами

Изменение цены

Protagonist Therapeutics Inc Прогноз

Целевая цена

By TipRanks

7.78% рост

Прогноз на 12 месяцев

Средняя 148 USD 7.78%

Максимум 175 USD

Минимум 110 USD

Основано на мнении 10 аналитиков Wall Street, спрогнозировавших целевые цены для Protagonist Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

10 ratings

Покупка

Удержание

Продажа

Основано на мнении 10 аналитиков, присваивавших рейтинги акциям Protagonist Therapeutics Inc – Данные за последние 3 месяца.

Настроения

By Acuity

120 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.